Applying to Clinical Trial: Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure

Apply to this TrialApply to the MRNA-1653 for Human Metapneumovirus and Human Parainfluenza Infection Trial

mRNA-1653 for Human Metapneumovirus and Human Parainfluenza Infection

“Some medicines have helped, while others haven’t. However, I feel there is something out there that will help to a greater degree.”

S.B.

47, New York, NY

See if you qualify in 3 minutes

Fill-in a few details and create your profile

We'll verify you meet the study requirements

Book a screening appointment with the study team

Compensation provided for your time

By clicking start, you agree to our Terms of Service and Privacy Policy

3m application